Real-world treatment patterns and outcomes among patients with HER2-positive unresectable or metastatic breast cancer in China.

ABSTRACT:

Background

Breast cancer is now the most commonly diagnosed cancer in the world and the leading cause of cancer mortality in women worldwide. In past few years, anti- human epidermal growth factor receptor-2 (HER2) therapy for metastatic breast cancer (mBC) has rapidly altered in China. This study aimed to describe treatment patterns and outcomes in patients with HER2-positive unresectable or metastatic breast cancer in the real-world setting.

Methods

This multicenter, retrospective analysis evaluated the treatment patterns and the efficacy in newly diagnosed HER2+ mBC patients between Jan 1, 2020 and Aug 31, 2022. Electronic medical records from 5 cancer centers in China were used.

Results

Among 865 patients, the most common first-line (1L) treatment regimen was dual

SUBMITTER: Huang J 

PROVIDER: S-EPMC12116439 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature